Why AtaiBeckley (ATAI) Is Building Its Valuation Case Around BPL-003’s Phase 3 Readiness

AtaiBeckley Inc. (NASDAQ:ATAI) is one of the small-cap stocks with potential to rise 1000 percent. The company’s investment case has become more concrete as BPL-003 moves closer to late-stage testing in treatment-resistant depression, rather than resting only on early psychedelic-drug enthusiasm. On June 8, it was reported that H.C. Wainwright reiterated a Buy rating and $25 price target on the stock after hosting AtaiBeckley management, with the firm saying BPL-003 remains the company’s core value driver as it prepares to initiate the Phase 3 ReConnection program in treatment-resistant depression.

That is important because AtaiBeckley is entering a more expensive but more valuation-relevant stage of development. In its May 12 business update, the company said BPL-003’s Phase 3 pivotal program remained on track to begin in Q2 2026, while VLS-01 Phase 2 topline data and BPL-003 Phase 2a Part 4 initial data were both expected in Q4 2026. The company also reported $209.9 million in cash, cash equivalents, and short-term securities as of March 31, 2026, and said its cash position was expected to fund operations into 2029, through anticipated BPL-003 Phase 3 topline readouts.

AtaiBeckley Inc. (NASDAQ:ATAI) is a clinical-stage biotechnology company developing rapid-acting mental health treatments, including BPL-003 for treatment-resistant depression, VLS-01 for treatment-resistant depression, and EMP-01 for social anxiety disorder.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.